Frontlight ResearchEarly access
Active, not recruitingNo phase
Imaging Quantification of Inflammation (IQI)
Key facts
- Who runs it
- The Cleveland Clinic
- Where
- Cleveland, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 50 people enrolled
- Started
- 22 Sept 2019
- Expected to end
- 30 Sept 2027
- Type of study
- Observational
- Treatments tested
- Standard of Care Imaging
- Record updated
- 4 March 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Any patient with a diagnosis of uveitis, who is deemed active or recently active (6 months) by a uveitis specialist
Who cannot take part
- Those with posterior uveitis, any allergy to fluorescein
- Poor view in fundus in both eyes which precludes image acquisition in those with posterior uveitis
- Corneal opacities which prevent image acquisition
- Inability to sign consent
Where in United States
- Cleveland Clinic Foundation-Cole Eye InstituteCleveland, United States
About the trial
What the trial wants to find out
1. Perform observational study utilizing real-time quantification of ocular inflammation to determine minimal important change.
Read full original descriptionShow less
Prospective use of changes in imaging quantification of inflammation (IQI) scores in determining treatment decisions both utilizing novel FA viewer software.
The group in the trial
- Imaging Analysis of patients with uveitis
Any patient with a diagnosis of uveitis, who is deemed active or recently active (6 months) by a uveitis specialist
Treatment: Standard of Care Imaging
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 4 March 2026